While I appreciate that it's possible to cut down the upfront costs with talented staff, it still seems that things like clinical trials will cost hundreds of millions of dollars (at least that's the price range I've seen for anti-malarial vaccination clinical trials) and still have a substantial chance of failure at later stage trials.
It would seem difficult to raise that kind of money from other than big pharma or typical pharma capital market sources who would want to see a large pay-off from such an risky investment (i.e. selling it in countries which could afford it).
It is not unlikely that some developing country like India, Brazil or Nigeria could pony up the money and provide access to regulatory fast tracks if the research seems promising enough.
It would seem difficult to raise that kind of money from other than big pharma or typical pharma capital market sources who would want to see a large pay-off from such an risky investment (i.e. selling it in countries which could afford it).
Best of luck in any case!